Potencial anticâncer e anti-inflamatório de adutos de Morita Baylis-Hillman

• Ano de defesa: 2015
• Autor(a) principal: Martins, Glaucia Verissímo Foheina
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal da Paraíba; Brasil; Biotecnologia; Programa de Pós-Graduação em Biotecnologia; UFPB
• Palavras-chave em Português: Adutos de Morita Baylis-Hillman; Morita Baylis-Hillman Adducts.; Células de leucemia mielóide humana K562; Apoptose; Canais iônicos; Ciclo celular; Inflamação; Line cells; Apoptosis; Ion channels; Cell cycle; Inflammation; CIENCIAS BIOLOGICAS
• Link de acesso: https://repositorio.ufpb.br/jspui/handle/tede/8587

Despite advances in research oncology field, has been an increased incidence and mortality caused by cancer, consisting in a major public health problem. Literature reports, that Morita-Baylis Hillman adducts (MBHA) show promising biological activities, such as: antiparasitic, against Leishmania, Plasmodium sp. and Trypanosomes, as well as effect on sea urchin embryo development. To assess anticancer and anti-inflammatory potential of three AMBH: A2CN, and A3CN, A4CN, we used various biological models. In MTT assay, the adducts were potentially toxic to eight cancer cell lines tested (HL-60, MOLT-4, K562, K562-Lucena, MCF-7, HT- 29, L929 and B16F10), however A2CN was the most cytotoxic, with IC50 lower for most cells. Acute myeloid leukemia cells, HL-60 and MOLT-4, were more sensitive and A2CN had IC50 22 and 21 μM in these cells. In chronic myelogenic leukemia cells, K562 and Lucena, A2CN presented IC50 of 58 and 60 μM, respectively. A2CN has been less cytotoxic to normal cells in peripheral blood and normal human fibroblasts (FN1), and IC50 was 78 and 126 μM, respectively. The action mechanism induced by A2CN in K562 cells was studied at 15, 30 and 60 μM. The cell viability has not altered when analyzed with propidium iodide, using flow cytometry, showing that A2CN not induced necrosis in these cells. A2CN increased mitochondrial membrane depolarization by 20 % at highest concentration tested. Cytotoxicity of A2CN in K562 cells were related to cell cycle arrest in G1-phase at 15 μM, and Sphase at highest concentration (60 uM) and ROS production increased at the highest concentration tested. Cell cycle arrest in S-phase was related to high expression mRNA of p21, p27 and p53, together with decreased expression of cyclin D1. A2CN also augmented expression of Kv1.3 and Kv3.1 genes in K562 cells treated with 60 μM. In electrophysiological assays, using the whole-cell "patch clamp", A2CN (120 μM) promoted increase total K+ current in K562, and conductance K+ ion was elevated. The potassium channel blocker, 4-aminopyridine (4-AP) (1 mM) decreased the A2CN cytotoxicity in K562 cells analyzed by MTT reduction, indicating that K+ channels have been involved in its cytotoxicity. The in vitro anti-inflammatory activity of A2CN, A3CN and A4CN was evaluated in LPS-stimulated RAW 264.7 macrophages. AMBHs did not reduced cell viability to concentration 20 μM, however, inhibited NO and ROS production induced by LPS. IL-1 β and IL-6 production was completely inhibited by 10 μM of AMBH, but no change in TNF-α levels. Expression of IL-1β and IL-6 genes were also altered by A2CN, A3CN and A4CN, but only A2CN was able to inhibit gene expression of cyclooxygenase-2 (COX-2). Therefore, it can be concluded that A2CN showed be potent anticancer activity, acting on molecular targets that are objects preclinical and clinical studies in oncology, such as p53, p21, p27 and cyclin D1, and proved to be a potent activator of potassium channels. Furthermore, adducts showed remarkable anti-inflammatory potential, a reduction of proinflammatory cytokines such as IL-1 β and IL-6 and COX-2 expression by A2CN.